ACRS
Price
$6.66
Change
+$0.03 (+0.45%)
Updated
Sep 27, 6:59 PM EST
40 days until earnings call
DXCM
Price
$92.09
Change
+$3.47 (+3.92%)
Updated
Sep 27, 6:59 PM EST
41 days until earnings call

Analysis and predictions ACRS vs DXCM

Header iconACRS vs DXCM Comparison
Open Charts ACRS vs DXCMBanner chart's image
Aclaris Therapeutics
Price$6.66
Change+$0.03 (+0.45%)
Volume$596.68K
CapitalizationN/A
DexCom
Price$92.09
Change+$3.47 (+3.92%)
Volume$3.73M
CapitalizationN/A
View a ticker or compare two or three
ACRS vs DXCM Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ACRS vs. DXCM commentary
Sep 28, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Hold and DXCM is a Sell.

COMPARISON
Comparison
Sep 28, 2023
Stock price -- (ACRS: $6.66 vs. DXCM: $92.09)
Brand notoriety: ACRS and DXCM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ACRS: 124% vs. DXCM: 164%
Market capitalization -- ACRS: $464.41M vs. DXCM: $33.38B
ACRS [@Medical Specialties] is valued at $464.41M. DXCM’s [@Medical Specialties] market capitalization is $33.38B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $6.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 0 FA rating(s) are green whileDXCM’s FA Score has 0 green FA rating(s).

  • ACRS’s FA Score: 0 green, 5 red.
  • DXCM’s FA Score: 0 green, 5 red.
According to our system of comparison, DXCM is a better buy in the long-term than ACRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 4 TA indicator(s) are bullish while DXCM’s TA Score has 4 bullish TA indicator(s).

  • ACRS’s TA Score: 4 bullish, 4 bearish.
  • DXCM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ACRS is a better buy in the short-term than DXCM.

Price Growth

ACRS (@Medical Specialties) experienced а -1.62% price change this week, while DXCM (@Medical Specialties) price change was -0.58% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.19%. For the same industry, the average monthly price growth was -5.40%, and the average quarterly price growth was -8.84%.

Reported Earning Dates

ACRS is expected to report earnings on Nov 07, 2023.

DXCM is expected to report earnings on Nov 08, 2023.

Industries' Descriptions

@Medical Specialties (-2.19% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for ACRS with price predictions.
OPEN
A.I.dvisor published
a Summary for DXCM with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DXCM($33.4B) has a higher market cap than ACRS($464M). DXCM YTD gains are higher at: -18.677 vs. ACRS (-57.714). DXCM has higher annual earnings (EBITDA): 684M vs. ACRS (-102.87M). DXCM has more cash in the bank: 3.64B vs. ACRS (120M). ACRS has less debt than DXCM: ACRS (458K) vs DXCM (3.37B). DXCM has higher revenues than ACRS: DXCM (3.2B) vs ACRS (31.2M).
ACRSDXCMACRS / DXCM
Capitalization464M33.4B1%
EBITDA-102.87M684M-15%
Gain YTD-57.714-18.677309%
P/E RatioN/A103.09-
Revenue31.2M3.2B1%
Total Cash120M3.64B3%
Total Debt458K3.37B0%
FUNDAMENTALS RATINGS
ACRS vs DXCM: Fundamental Ratings
ACRS
DXCM
OUTLOOK RATING
1..100
6762
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
9755
PRICE GROWTH RATING
1..100
8664
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACRS's Valuation (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for DXCM (87) in the Medical Specialties industry. This means that ACRS’s stock grew somewhat faster than DXCM’s over the last 12 months.

DXCM's Profit vs Risk Rating (40) in the Medical Specialties industry is somewhat better than the same rating for ACRS (100) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew somewhat faster than ACRS’s over the last 12 months.

DXCM's SMR Rating (55) in the Medical Specialties industry is somewhat better than the same rating for ACRS (97) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew somewhat faster than ACRS’s over the last 12 months.

DXCM's Price Growth Rating (64) in the Medical Specialties industry is in the same range as ACRS (86) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew similarly to ACRS’s over the last 12 months.

DXCM's P/E Growth Rating (90) in the Medical Specialties industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that DXCM’s stock grew similarly to ACRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACRSDXCM
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
66%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 1 day ago
66%
Advances
ODDS (%)
Bullish Trend 17 days ago
82%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 1 day ago
75%
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMEFX32.420.22
+0.68%
Nuveen Mid Cap Growth Opps R6
GEBCX8.370.01
+0.12%
Goldman Sachs ESG Em Mkts Eq C
RISAX20.75-0.01
-0.05%
Manning & Napier Rainier Intl Discv S
CLREX43.71-0.06
-0.14%
Columbia Balanced Inst2
PHLCX16.77-0.12
-0.71%
PGIM Jennison Health Sciences C

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with STRRP. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then STRRP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
+0.45%
STRRP - ACRS
52%
Loosely correlated
+2.48%
UFPT - ACRS
37%
Loosely correlated
+1.99%
DXCM - ACRS
32%
Poorly correlated
+3.92%
MXCT - ACRS
32%
Poorly correlated
+1.99%
AZTA - ACRS
31%
Poorly correlated
N/A
More

DXCM and

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with SYK. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then SYK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
+3.92%
SYK - DXCM
51%
Loosely correlated
-2.56%
PODD - DXCM
48%
Loosely correlated
+1.51%
ABT - DXCM
47%
Loosely correlated
-0.73%
ISRG - DXCM
46%
Loosely correlated
+0.24%
RVTY - DXCM
46%
Loosely correlated
+0.11%
More